Wegovy Gains Approval for Treating Obesity in Adolescents
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Semaglutide is a glucagon-like peptide-1 receptor agonist.
From 2010 to 2019, greatest percent increase in cancer deaths and DALYs was from metabolic risks
The approval was based on data from a phase 4 study which included patients 12 to 17 years of age with a BMI at the 95th percentile or greater standardized for age and sex.
Three-quarters of all psychiatric disorders occur by early adulthood (mid-20s). This fact suggests that bio-psychosocial factors occurring from the fetal period through early adulthood could play a crucial role in risk. This nonsystematic review sought to synthesize key epidemiological evidence of relevant risk factors.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist primarily used to improve glycemic control in adults with type 2 diabetes. One favorable side effect of semaglutide is weight loss, and researchers have now studied its use in adults with overweight or obesity and without diabetes.
Approximately 5% to 10% of shift workers, including many health care professionals, have shift work disorder, a circadian sleep-wake cycle disorder defined by poor quality sleep.
Author describes efficacy and safety information on red yeast rice in the treatment of dyslipidemia.
A recent review underscores the possible adverse effects of ketogenic diets including increased risks for heart disease, cancer, diabetes, and kidney stones.
Researchers used global baseline data to examine cardiovascular disease risk factors among middle-aged people with HIV.